1. Home
  2. Vol. 8 Issue. 2 (February-2023) EPRA International Journal of Research & Development (IJRD)

A COMPREHENSIVE REVIEW ARTICLE ON FINERENONE

Dr.Sanjay Prajapati, Dr. Pratik Prajapati, Kajal Gondaliya
--, --
DOI:
Abstract
Finerenone is a Novel selective Non-steroidal Mineralocorticoids Receptor Antagonist. Finerenone is indicated for the treatment of Chronic kidney disease (stage 3 and stage 4) associated with type 2 diabetes in adults. Finerenone blocks the MR receptor so that the progression of chronic kidney disease is control. Finerenone belongs to the BCS class-II, low solubility and low half life and bioavailbility.
Keywords: Finerenone, Chronic kidney disease, Solubility, BCS Class.
Journal Name :
EPRA International Journal of Research & Development (IJRD)
VIEW PDF
Published on : 2023-02-25
Vol : 8
Issue : 2
Month : February
Year : 2023
ABOUT EPRA JOURNALS
The principle reason for EPRA Journals is to give a Research discussion to the world, over to share great learning. It expects to be the voice of Scholars around the world. One of its establishing standards is that of backing of the scholastic research field. EPRA plans to make an research environment that empowers all researchers to have a voice. As being what is indicated, the founder believe that all researchers have something valuable to add to EPRA that others may gain from. Consequently, we are begun journal in all disciplines. EPRA publishes the most astounding quality journals and conveys this research to the greatest conceivable crowd. More
QUICK LINKS
FOR AUTHORS
Copyright © 2024 EPRA JOURNALS. All rights reserved
Developed by Peace Soft